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IN VITRO EFFECTS OF DIFFERENT PLATELET-RICH PLASMA
PREPARATIONS ON HUMAN SYNOVIOCYTE RESPONSE
A. Rofﬁ, E. Assirelli, G. Filardo, L. Pulsatelli, V. Canella, E. Mariani,
E. Kon, M. Marcacci, A. Facchini. Rizzoli Orthopaedic Inst., Bologna, Italy
Purpose: Osteoarthritis (OA) is a common disease that will affect
almost half the population at some point in their life through pain and
decreased functional capacity. Numerous approaches have been pro-
posed, but none can be considered an ideal procedure for the treatment
of joint degenerative processes.
Among the new therapeutic options, Platelet Rich Plasma (PRP), an
autologous blood derived product, is emerging as promising intra-
articular treatment for cartilage degenerative lesions. However, results
on the potentiality of this biological treatment are still controversial and
confounding, due to the lack of well-designed studies and to the dif-
ferent preparation procedures. Aim of this study was to increase
knowledge concerning the biological effect of PRP treatment on clin-
ically relevant joint cells. For this purpose, we compared the effect of
two different PRP preparations on the expression of a panel of bio-
molecules by OA cultured synoviocytes.
Methods and Materials: Blood collected from 7 volunteers was used to
obtain two PRP preparations: a one-spinning procedure, aimed at
obtaining a pure platelet concentrate (P-PRP) without leukocytes but
with a limited number of platelets, and a two-spinning procedure,
aimed at obtaining a higher platelet concentration but with the pres-
ence of leukocytes (L-PRP). Synovial tissues were collected from OA
patients (Kellgren-Lawrence grade II- III) undergoing knee replacement
surgery.
Gene expression analysis of IL-1b, IL-6, IL-8, TNF, MMP-13, TIMP-1, -3,
-4, VEGF, TGFb1, IL-10, IL-4,-13, FGF-2, HGF, Hyaluronic acid synthases
(HAS)-1, -2, -3 was performed at day 7 (in agreement with weekly
clinical administration of PRP) by semi- quantitative RT-PCR. HA
(Hyaluronic Acid) production was analyzed in culture supernatants by
ELISA. Statistical analysis was carried out using the General Linear
Model.
Results
a) White blood cells (WBC) were present only in L-PRP, platelets con-
centrations were signiﬁcantly higher in L-PRP than P-PRP.
b) HA production and HAS gene expression did not seem to be modu-
lated by PRP
c) IL-1b, IL-8 and FGF-2 were signiﬁcantly induced by L-PRP, whereas
HGF was down-modulated by L- PRP compared to P-PRP.
d) IL-1b and IL-8 expression levels signiﬁcantly correlated with WBC
count and showed a dose-response effect to L-PRP
e) HGF mRNA expression showed an inverse correlationwith bothWBC
and platelet count.
f) MMP-13 expression inversely correlated with WBC number, whereas
TIMP-4 inversely correlated with platelet count.
h) HAS-2 and HAS-3 had respectively direct and inverse correlation
trends with WBC count.
Conclusion: Our data in OA synoviocytes indicate that L-PRP is able to
sustain long-term up-regulation of pro-inﬂammatory factors, such as
IL-1b, IL-8 and FGF-2 compared to P-PRP, together with a down mod-
ulation of HGF and TIMP-4 expression. These last two factors that have
been recognized as anti-catabolic mediators in cartilage. Further
researches are needed to clarify the inﬂuence of different concen-
trations of WBC on the bioactivity of PRP and their potential beneﬁcial
effect. Since WBC-platelet interaction may promote the biosynthesis of
other factors that facilitate the resolution of inﬂammation, such as
lipoxins, and given their involvement in immune-response, the opti-
mization of their concentrations in PRP products might lead to mini-
mizing or avoiding the detrimental effects ascribed to leucocytes and
exploit their beneﬁcial properties.
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GENERATING NUCLEUS PULPOSUS-LIKE CELLS FROM HUMAN
ADIPOSE STROMAL CELLS: A FIRST STEP TOWARDS THE
REGENERATION OF INTERVERTEBRAL DISC
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O. Hamel y,x, L. Lescaudron k,y, J. Clouet y,{, J. Guicheux y,#. y INSERMU791-
LIOAD, Univ. of Dental Sch., Nantes, France; zAnatomopathology Dept.,
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kUniv. of Sci.s, Nantes, France; { Pharmacy Dept., CHU, Nantes, France;
# PHU 4 OTNN, CHU, Nantes, FrancePurpose: Intervertebral disc (IVD) degeneration is one of the major
causes of low back pain. Whereas some pharmacological and surgical
symptomatic treatments are currently available; an efﬁcient, safe and
reliable etiological treatment is still lacking. It is now well-established
that the Nucleus pulposus (NP) is prematurely affected by degenerative
events, mainly starting with the apoptotic death of the NP resident
mature cells namely the nucleopulpocytes. In this context, repopulating
a damaged NP with functional regenerative cells seems to be a prom-
ising approach for long term regeneration of IVD.
Since Growth Differentiation Factor 5 (GDF5) plays a crucial role in IVD
anabolism and biological activity of nucleopulpocytes, we questioned
whether GDF5 may be an efﬁcient tool to drive the nucleopulpogenic
differentiation of human Adipose Stromal Cells (hASC). In this context,
the aim of the present work was to investigate the effects of supple-
menting a chondrogenic mediumwith GDF5 on the in vitro production
of functional nucleopulpocytes from hASC.
Methods: Human ASC were isolated from adipose tissue of 3 informed
donors. They have been cultivated in pellets (500.000 cells/pellet) for
28 days in the presence of low oxygen tension (5%) with a chondro-
genic medium (TGF-b1 and insulin) enriched or not with GDF5
(100ng/ml). The nucleopulpogenic differentiation of hASC has been
evaluated by determining the expression levels of ACAN, COL2A1,
PAX1, OVOS2 and CD24 transcripts by RT-qPCR. The levels of the
corresponding proteins in hASC pellets have been assessed by
immunohistochemistry analyses. In parallel, the speciﬁcity of the hASC
commitment has been determined by analysing the expression of
osteogenic-, adipogenic- and chondrogenic-related markers by Taq-
man Low Density Array. To decipher the role of the Smad pathways
during the nucleopulpogenic differentiation, hASC were cultivated in
the presence of the GDF5-enriched chondrogenic medium with or
without SB505124 (5 mM) or dorsomorphin (5 mM). The respective
speciﬁcity of these chemical inhibitors was previously analysed by
western blot using phospho-speciﬁc antibodies against Smad2/3 and
Smad1/5/8.
Results: Our RT-qPCR and immunohistochemistry data showed that
hASC cultivated in the presence of a GDF5-enriched chondrogenic
medium expressed nucleopulpocyte markers (ACAN, COL2A1, PAX1,
OVOS2 and CD24) at the transcript and protein levels. A time course
experiment demonstrated that hASC express nucleopulpocyte markers
as early as 21 days of culture. Furthermore, the osteogenic-, adipogenic-
and chondrogenic-relatedmarkers remain at a barely detectable level of
expression. Concerning the role of Smad pathways during the nucleo-
pulpogenic differentiation of hASC, our western blot data demonstrated
that SB505124 and dorsomorphin respectively inhibit the phosphor-
ylation of Smad2/3 and Smad1/5/8 and thus respectively block the TGF-
b and GDF5 canonical pathways. Whereas SB505124 was found to
prevent the nucleopulpogenic differentiation of hASC, dorsomorphin
did not signiﬁcantly affect this differentiation process.
Conclusions: Our data demonstrate that human ASC cultivated in the
presence of a GDF5-enriched chondrogenic medium can be committed
towards the nucleopulpocyte lineage. This commitment seems to be
reproducible, robust and speciﬁc. Our results also suggest that the
canonical TGF-b pathway (Smad2/3) plays a pivotal role for the nucle-
opulpogenic commitment of hASC. Whether the in vitro generation of
functional nucleopulpocytes may help us design regenerative medicine
strategies remains to be further evaluated in suitable animal models of
disc degeneration.
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REGENERATIVE THERAPY WITH MESENCHYMAL STEM CELLS FROM
ADIPOSE TISSUE AND PLASMA RICH IN GROWTH FACTORS IN
CANINE HIP OSTEOARTHRITIS
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Purpose: The aim of this study was to compare the effect of adipose
mesenchymal stem cells (aMSC) (Dog Stem), Plasma rich in growth
factors (PRGF) (PRGF-Endoret) and the combination of these two
therapies in the treatment of canine hip osteoarthritis (OA).
Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S429Methods: The study was performed in 66 dogs with hip degenerative
osteoarthritis (documented by X-Rays and clinical ﬁndings). The
inclusion criteria were healthy animals weighing more than 18 kg, with
presence of hip OA. Animals were randomly assigned to one of these
three study groups:
 aMSC: single intraarticular injection of autologous adipose mesen-
chymal stem cells obtained by Stem Cells method. The adipose tissue
was obtained by open biopsy and cultivated in Stem Cells Laboratories
(Belgium) (2cc containing 30 million mesenchymal stem cells) (n ¼ 17).
 PRGF: single intraarticular injection of PRGF obtained by Anitua’s
method. Citrate tubes for PRGF centrifuged at 460G during 8 minutes
(n ¼ 32).
 PRGF þ aMSC: single intraarticular injection of the combination of
aMSC obtained by Stem Cells method and PRGF obtained by Anitua’s
method (n ¼ 17)
Dogs were evaluated at baseline, and one, three and six months after
intraarticular inﬁltration of the treatment. The primary outcome vari-
able was OA degree (assessed by the Bioarth Osteoarthritis Scale:
radiographic ﬁndings (mild, moderate or severe), owners questionnaire
for functional limitation (measurement scale: 0 to 23 points), joint
mobility (measurement scale: 0 to 7 points) and muscular atrophy).
Additional measures included the range of movement (extensionminus
ﬂexion, measured in degrees), visual analogic scale (VAS) to assess pain
relief improvement performed by the owner and the veterinarian,
owner satisfaction questionnaire which included one question about
the treatment efﬁcacy and one to the outcome of its quality of life, and
the presence of adverse effects secondary to the treatment applied
(Aes).
Data was analyzed with the SPSS 20.0 program. The nonparametric
Kruskal-Wallis and U Mann-Whitney tests were used to compare non-
categorical variables between groups at each time. To evaluate in each
group the evolution in time of these variables, the Related-samples
Wilcoxon signed rank test was used. To assess the categorical ones,
crosstabs with contingency coefﬁcient were performed.
Results: OA degree assessed radiologically did not vary within groups
and there were no aggravate until 6 months. However, in functional
limitation, joint mobility, range of movement, owner’s and veter-
inarians perception of pain (VAS) and owner satisfaction of the treat-
ment, a clear improvement was seen since the ﬁrst month of study,
maintaining up to six months in the three groups, without any differ-
ences between the aMSC and aMSCþPRGF groups. Worse results on
joint mobility and range of movement were observed in the PRGF group
compared to the other two groups at 6 months post-treatment. There
were no adverse effects during the study.
Conclusions: The three treatments were very effective in the control of
pain and the recovery of joint functionality in the dogs included in this
study. We hypothesized that the two-aMSC groups (aMSC and
aMSCþPRGF) performed better because the effect of PRGF increases the
synthesis of chondrocytes, collagen and proteoglycans as well as acting
as a coordinator to regulate homeostasis and proper functioning of the
cartilage, whereas the aMSCs could differentiate into different celular
linages participating in the repair of cartilage lesions. Furthermore, the
authors are of the opinion that in the long term, the addition of PRGF to
aMSC promotes cell viability and extends cell life-span.
774
FULL-THICKNESS CARTILAGE DEFECTS REPAIRED BY HUMAN
INDUCED PLURIPOTENT STEM CELLS (IPSCS)-DERIVED
MESENCHYMAL STEM CELLS AND PLGA SCAFFOLDS
D. Shi, X. Xu, Q. Jiang. Sports Med. and Adult Reconstruction, Nanjing,
China
Purpose: To evaluate the utility of human induced pluripotent stem
cells (iPSCs)-derived mesenchymal stem cells for full-thickness carti-
lage defects repair.
Methods: 36 New Zealand White Rabbits were used to create full-
thickness cartilage defects in the patellar groove of both femurs. The left
knees were used to be transplanted with graft, the right knees were left
untreated. Human iPSCs were ampliﬁed and then cultured through
multiple steps including embryoid body (EB) formation, cells outgrowth
from EBs and monolayer culture of spindle-like cells from EBs to gen-
erate mesenchymal stem cells. Cells were then plated in PLGA scaffoldsand incubated in chondrogenic medium for 5 days or 21 days. The
induced cell-scaffold composites were implanted into cartilage defects.
The animals were divided into 3 groups according to the difference of
grafts, 12 cell-scaffold composites induced for 5 days in vitro (Group A),
12 cell-scaffold composites induced for 21 days in vitro (Group B), 12
scaffolds (Group C). Rabbits were sacriﬁced at 3weeks and 6 weeks after
surgery. Macroscopic and histologic were used to measure the defects
repair.
Results: At 3weeks, no difference was detected among these three
groups. No chondrocytes were found and the cartilage defects were
poorly repaired. At 6 weeks, still no chondrocytes were found in Group
C. However, cartilage-like tissue ﬁlled the cartilage defects in Group A
and Group B, and no tumor formed.
Group B did not show signiﬁcant better than Group A.
Conclusions: iPSCs have the potential to repair the cartilage defects in
vivo. 5 days’ chondrogenic induction in vitro is sufﬁcient for iPSCs to
regenerate cartilage in vivo. Long time induction up to 21 days did not
show better results.
